Week Ending March 15, 2021

How The Latest Lung Cancer Screening Guidelines Impact Women, Race, Addiction And Covid-19
“The second-most common cancer and leading cause of cancer death in the United States may see its numbers drop.”

The Centers for Medicare & Medicaid Services Requirement for Shared Decision-making for Lung Cancer Screening
“In 2011, the National Lung Screening Trial (NLST) demonstrated that annual screening with low-dose computed tomography (CT) reduced lung cancer mortality among current or former heavy tobacco users.1 While the trial found that low-dose CT screening was beneficial, screening also posed important harms, including false-positive results, radiation exposure, overdiagnosis, incidental findings, and complications from invasive procedures, particularly in participants who did not have lung cancer.”

‘A Breath of Fresh Air’: FDA’s Cosela Approval May Improve Quality of Life in Lung Cancer
“The Food and Drug Administration’s (FDA) recent approval of a first-in-its-class drug, Cosela (trilaciclib), is refreshing for patients and providers, according to a lung cancer expert.”

THIS is how lung cancer patients can benefit from yoga as suggested by grandmaster Akshar
“Yoga builds strength, stamina, and flexibility for the body. This is extremely crucial in order to gain maximum benefits from the treatment and heal in a healthy and holistic manner. Find out how yoga can help in healing lung cancer patients and its additional benefits.”

What You Need to Know About the Major Update to Lung Cancer Screening Guidelines
“There are new guidelines for lung cancer screening, which will make many more people—especially women and Black people—eligible for screening earlier in their lives.”

Trial Assessing Novel Drug in Patients With Previously Treated Non-Small Cell Lung Cancer Fails to Meet its Goal of Improving Survival
“The phase 3 CANOPY-2 trial failed to meet its main goal of improving overall survival in patients with locally advanced or metastatic non–small cell lung cancer whose disease progressed on or after prior platinum-based chemotherapy and treatment with PD-1/L1 inhibitor therapy, according to Novartis.”

Roundtable Discussion: How to Treat a Patient With Non–Small Lung Cancer and When to Use the PACIFIC Regimen
“Jessica Donnington, MD, professor of Surgery and chief, of the Section of Thoracic Surgery at the University of Chicago Medicine, led a discussion with a group of peers regarding treatment of non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.”

Looking at the Big Picture of Small Cell Lung Cancer
“Small cell lung cancer is a unique type of lung cancer affecting 13% to 15% of all lung cancer cases, and treating the disease is based on if and how the cancer spread through the body, according to a presentation at CURE® Educated Patient® Lung Cancer Summit.”

FDA Approves Companion Diagnostic for ALK-Positive Non–Small Cell Lung Cancer Treatment
“The FDA has approved the VENTANA ALK (D5F3) CDx assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer (NSCLC) who are eligible to receive treatment with lorlatinib (Lorbrena).”